Effective March 3, 2014, Paul M. Antinori will transition from his role as General Counsel and Secretary of The Medicines Company to thereafter create and lead the company's global government affairs function and continue to assist on significant transactions and other matters. Subsequent to Mr. Antinori's role change, he will no longer be a Section 16 officer or executive officer of the company. Stephen M. Rodin, currently Vice President, Deputy General Counsel for the company, will assume the role of Senior Vice President, General Counsel and Secretary as of March 3, 2014.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | +0.14% | -0.05% |
2020 | The Medicines Company Announces Board Changes | CI |
2020 | The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care | CI |
1st Jan change | Capi. | |
---|---|---|
-0.05% | 6.79B | |
+25.24% | 45.32B | |
+34.85% | 24.51B | |
+29.56% | 16.85B | |
+21.32% | 14.62B | |
+70.51% | 14.16B | |
-10.06% | 6.73B | |
+15.74% | 5.82B | |
-8.87% | 5.73B | |
+10.29% | 4.93B |
- Stock Market
- Equities
- MDCO Stock
- News The Medicines Company
- The Medicines Company Announces Management Changes, Effective March 3, 2014